ERBB2 and colorectal cancer: Given that the three signaling pathways are the most important abnormal signaling pathways in colorectal cancer [49–51], combining HER2-targeted therapy with above pathway inhibitors may have potential efficacy in colorectal cancers with HER2 alterations.